Radisens wins Red Herring Top 100 Europe Award
Cork – April 14, 2016 – Radisens Diagnostics announced today it has won the Red Herring Top 100 Europe award, a prestigious award recognizing Europe’s leading private companies and celebrating these startups’ innovations and technologies across their respective industries.
Red Herring Top 100 Europe enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1,200 privately financed companies each year in the European Region. Since 1996, Red Herring has kept tabs on these up-and-comers. Red Herring’s Top 100 list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring’s editors were among the first to recognize that companies such as Alibaba, Facebook, Google, Kakao, Skype, SuperCell, Spotify, Twitter, and YouTube would change the way we live and work. Thousands of the companies most interesting and innovative companies have graced the Top 100 list over the years.
Red Herring’s editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technological innovation, management quality, overall business strategy and market penetration. This assessment was complemented by a review of the track records and standings of similar startups in the same verticals, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models in Europe.
The Red Herring editorial team selected the most innovative companies from a pool of hundreds from across Europe. The nominees were evaluated on 20 main quantitative and qualitative criterion: they include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries.
About Radisens Diagnostics
Radisens, a private venture-backed diagnostics company, is breaking new ground in the decentralisation of routine blood testing from central reference laboratories into physician offices, outpatient clinics, pharmacies and other near-patient test settings. With a finger-prick of blood, this multi-mode diagnostic device will return laboratory-grade results instantly within a patient’s physician visit.
Radisens’ initial menu concentrates on panels for those suffering with high-burden chronic disease resulting in improved patient outcomes and more efficient healthcare management. By integrating immunoassay, clinical chemistry, cell counting and other test modes, this near-patient device will finally open blood testing access to all with instant diagnosis and monitoring. The fear or needles, the many anxious days or weeks of waiting for results, the multiple physician visits, will all be things of the past.